Retrospective modeling study of ChatGPT (GPT 4) warfarin dose adjustment in patients with INRs outside the therapeutic range

OBJECTIVE: This retrospective, modeled study evaluates the accuracy of ChatGPT (GPT-4)-based warfarin dose adjustments compared to clinician recommendations at the Cardiology Clinic of Konya City Hospital, focusing on patients with international normalized ratio (INR) values outside the therapeutic range (2-3). We hypothesized that ChatGPT could provide reliable, consistent dose guidance. METHODS: We reviewed the records of warfarin-treated patients from 1 June 2022 through 24 November 2024. Clinical data used by physicians (e.g. baseline INR, warfarin indication, comorbidities, and current dose) were provided to ChatGPT to generate hypothetical weekly dose recommendations. ChatGPT's impact on INR normalization was modeled using standard dose-response assumptions and compared with actual outcomes under physician-guided therapy. RESULTS: A total of 180 patients met the inclusion criteria. ChatGPT's recommended doses were within ±1 mg/week of physician prescriptions in 74% of cases and within ±2 mg/week in 84%. The mean physician dose was 28.0 ± 6.1 mg/week versus ChatGPT's 27.5 ± 5.9 mg/week (p = .12). Seventy-two percent of patients achieved therapeutic INR under physician-managed dosing, while the model suggested a 69% success rate for ChatGPT-guided dosing (p = .15). Real-world adverse events were infrequent under physician management (1.1% major bleeding, 0.6% thrombotic events). CONCLUSION: In this retrospective, exploratory analysis with modeled outcomes, ChatGPT's weekly dose suggestions showed high concordance with clinician dosing. These findings are hypothesis-generating and do not establish clinical efficacy or safety; prospective, physician-supervised trials-potentially integrated with home INR monitoring-are required for validation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed research on anticoagulant and antithrombotic drug development relevant to leech-derived therapeutics. Indexed in PubMed and verified against the NCBI record.

Explore cómo esta investigación se conecta con la práctica clínica

More peer-reviewed studies in Desarrollo de fármacos.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)
• In-vitro antileishmanial potential of peptide drug hirudin — Khan H et al. (2017)
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines — Garcia DA, Baglin TP, Weitz JI, Samama MM (2012)
• Direct thrombin inhibitors — Lee CJ, Ansell JE (2011)
• Updates on Use and Monitoring of Direct Thrombin Inhibitors — Navaei A et al. (2026)

Browse all ASH-analysed research →